Fenfluramine treatment in infantile autism. Neurochemical, electrophysiological, and behavioral effects.
As part of a multicenter, collaborative project, response to fenfluramine was assessed in 10 autistic outpatients. After 4 months of treatment, blood serotonin concentrations decreased an average of 60 per cent and returned to pretreatment levels after 2 months on placebo. This reduction was accompanied by a decrease in certain behavioral symptoms, including motor activity, distractibility, and mood disturbances. Baseline evoked potential recordings indicated that autistic patients tended to have a larger amplitude of the P3 component to frequent tones as compared to age-matched controls. A tendency toward "normalization" of the P3 effect was observed during the medication trial and during the final placebo period. Treatment response was not related to initial serotonin levels, and no major clinical side effects were associated with fenfluramine.
D000293:Adolescent; D000553:Ambulatory Care; D001288:Attention / Q000187:drug effects; D001321:Autistic Disorder / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001933:Brain Stem / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004644:Emotions / Q000187:drug effects; D005071:Evoked Potentials; D005260:Female; D005277:Fenfluramine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D010349:Patient Compliance; D010919:Placebos; D012701:Serotonin / Q000097:blood
D010919:Placebos; D005277:Fenfluramine; D012701:Serotonin